[Observational survey of the French Urological Association Oncology Committee (CCAFU) evaluating the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment].

Enquête observationnelle du Comité de cancérologie de l’association française d’urologie (CCAFU) sur la pratique des instillations postopératoires précoces (IPOP) de mitomycine C pour le traitement des tumeurs de vessie n’infiltrant pas le muscle (TVNIM)

Y. Neuzillet (1, 2) , P. Colin (3) , E. Comperat (4, 5) , F. Dubosq , N. Houédé (6, 7) , S. Larre (8) , A. Masson-Lecomte (9) , G. Pignot (10) , Pascal Puech (11) , M. Roumiguié (12) , E. Xylinas (13, 14) , A. Mejean (4, 5) , M. Roupret (15, 14)

1 Hôpital Foch [Suresnes]
2 UVSQ - Université de Versailles Saint-Quentin-en-Yvelines
3 Hôpital Privé La Louvière
4 CHU Pitié-Salpêtrière [AP-HP]
5 UPMC - Université Pierre et Marie Curie - Paris 6
6 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
7 IRCM - U1194 Inserm - UM - Institut de Recherche en Cancérologie de Montpellier
8 Hôpital universitaire Robert Debré [Reims]
9 Service d'urologie [Mondor]
10 Service d'urologie
11 CHRU Lille - Centre Hospitalier Régional Universitaire [CHU Lille]
12 Département d'Urologie-Andrologie et Transplantation Rénale [CHU Toulouse]
13 Service d'urologie [CHU Cochin]
14 UPD5 - Université Paris Descartes - Paris 5
15 HEGP - Hôpital Européen Georges Pompidou [APHP]

OBJECTIVE: To evaluate the practice of immediate postoperative instillation (IPOP) using mitomycin C for non-muscle invasive bladder cancer (NMIBC) treatment by urologists members of the French Association of Urology (AFU). MATERIAL AND METHOD: Internet-based observational survey evaluating indications and practical modalities of IPOP in NMIBC treatment using questionnaire sent in May 2014 to 915 urologists. RESULTS: Two hundred ninety-eight urologists participated in the survey (response rate: 32.6%) and 57% prescribed the IPOP. The median frequency of IPOP prescription was 3.3%, and was higher in the academic public sector. The CASE recommendations were self-assessed as known or well-known in 67% of cases. The selections criteria for IPOP were adequately identified by 62% of urologists, without differences according to sectors of activity. The IPOP prescription modalities were declared as an obstacle to the completion for 41.9% of urologists, and especially in the private sector. Completion times of IPOP were declared <24h in 91% of cases. We see that 28.5% of urologists prescribed an urinary alkalization. The average frequency of complications of IPOP was 0.91 per urologist. CONCLUSIONS: The IPOP prescription frequency was higher among urologists practicing in the academic sector. Neither the level of knowledge of the recommendations nor the frequency of complications of IPOP had explained this difference. However, the prescription modalities were more frequently reported as an obstacle to their completion in the private sector. LEVEL OF EVIDENCE: 3.

Mots clés: Enquête de pratique; Immediate postoperative instillation; Instillation postopératoire précoce; Non-muscle invasive bladder cancer; Practice survey; Secteur d’activité professionnel; Sector of professional activity; Tumeur de vessie n’infiltrant pas le muscle

Domaines: Urologie et Néphrologie

Y. Neuzillet, P. Colin, E. Comperat, F. Dubosq, N. Houédé, et al.. Enquête observationnelle du Comité de cancérologie de l’association française d’urologie (CCAFU) sur la pratique des instillations postopératoires précoces (IPOP) de mitomycine C pour le traitement des tumeurs de vessie n’infiltrant pas le muscle (TVNIM). Progrès en Urologie, 2016, 26 (3), pp.181 - 190. ⟨10.1016/j.purol.2015.12.002⟩. ⟨hal-01908561⟩